More recent studies have also shown that in vitro OPG (through the inhibition of TRAIL- induced apoptosis) could be a survival factor for prostate cancer cells [10], breast cancer cells [11] and multiple myeloma cells [12] (figure 1). This evidence concerns the gene TNFSF10 and plasma cell myeloma.